Drug Database
DO

doxorubicin hydrochloride (Libod / Libaoduo)

✓ Approved

Shanghai Fudan-Zhangjiang · TOP2A · 小分子

什么是 doxorubicin hydrochloride?

doxorubicin hydrochloride 是一种小分子,由Shanghai Fudan-Zhangjiang研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)。

药物档案

商品名Libod, Libaoduo
公司Shanghai Fudan-Zhangjiang
药物类别小分子
分子靶点TOP2A
给药途径Injectable (Others), Intravenous (IV)
状态Approved

作用机制

分子靶点

doxorubicin hydrochloride 作用于 1 个分子靶点:

TOP2ADNA topoisomerase II alpha (TOP2alpha, TOPIIA)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

doxorubicin hydrochloride 针对 4 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Breast cancer✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Kaposi's sarcoma✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Ovarian cancer✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Plasma cell myeloma✓ Approved

相关研究文献

PubMedHaematologica2026-11-19

Preserving liposomal anthracycline exposure and reconsidering radiotherapy in frontline therapy of older adults with advanced-stage classical Hodgkin lymphoma. Comment on: "Nivolumab with doxorubicin, vinblastine, and dacarbazine in older adults with classic Hodgkin lymphoma: do S1826 results hold up in the real world?"

Giordano Claudia C, Picardi Marco M

PMID 43053699
阅读全文 →
PubMedBiotechnology and applied biochemistry2026-11-19

Liposomal Encapsulation of Quercetin Using Clerigar Anchored Lecithin for Enhanced Cytotoxity Towards HeLa Cells.

Banerjee Tridib T, Das Ujjal U, Das Saptydeep S, Chowdhury Dhritiman D et al.

Quercetin is a dietary polyphenol and is regarded as a potential chemo-protector towards many tumor-related processes. Here, we have developed a liposomal system for encapsulation of this hydrophobic polyphenol using pH-driven method. Pristine quercetin-loaded liposomes (QLs) and clerigar-coated quercetin-loaded liposomes (CRQLs) were prepared using active loading method using Box-Behnken design. Particle size, zeta potential, transmission electron microscope (TEM), and encapsulation efficiency were assessed to characterize the liposomes. Clerigar coating improved the stability and encapsulation efficacy of the liposomal system. It was discovered that quercetin release from the liposomal system in Ringer's lactate (RL) medium followed the order free quercetin (99.45% ± 0.35%) > QLs (45.75% ± 0.75%) > CRQLs (19.75% ± 0.24%). Again, in simulated gastric fluid (SGF) and simulated intestinal fluid (SIF), similar trends were observed with release percentage values, free quercetin (99.83% ± 0.45%) > QLs (54.10% ± 0.38%) > CRQLs (38.38% ± 0.47%), and free quercetin (99.23% ± 0.55%) > QLs (46.36% ± 0.47%) > CRQLs (32.23% ± 0.67%), respectively. Furthermore, by producing more reactive oxygen species (ROS) that cause cell death, CRQLs are more cytotoxic to HeLa cells than QLs. Isothermal calorimetric titrations revealed that quercetin undergoes hydrophobic interactions with the lecithin liposomes, whereas electrostatic interactions prevail when QLs interact with 0.20% clerigar solution. The higher stability and lesser release tendency of CRQLs in our strategy together with low IC50 (∼15 µM) in HeLa and low cytotoxicity in HaCaT (IC50 ∼220 µM) indicates a prospective outcome.

PMID 43053497
阅读全文 →
PubMedBMC nutrition2026-11-19

Home enteral nutrition management in postoperative oral cancer patients: an evidence summary.

Wu Yifan Y, Zeng Changjuan C, Hou Lili L, Wang Yueping Y et al.

This study aimed to establish a standardized management system for home enteral nutrition (HEN) for patients with postoperative oral cancer and provide scientific guidance for clinical professionals by systematically searching relevant literature and summarizing the best evidence. Literature retrieval was performed systematically across Chinese and English databases following the "5S" evidence hierarchy model to identify studies addressing home nutritional management in postoperative oral cancer patients. Eligible articles underwent rigorous screening, methodological appraisal, and data synthesis to extract high-quality clinical evidence. The final review encompassed a total of 15 articles, including 6 evidence-based guidelines, 4 systematic reviews, 1 clinical decision, 2 expert consensuses, and 2 evidence summaries. Through systematic induction and integration, a total of 29 pieces of best evidence were synthesized and categorized into five key domains: establishment of nutrition management team, nutrition screening and assessment procedures, implementation standards for HEN, health education and care strategies, and monitoring and follow-up mechanisms. The best-evidence-based evidence summarized in this study can provide a reference for the formulation of HEN management plans for postoperative patients with oral cancer. This study was conducted in accordance with the evidence summary reporting guidelines established by the Fudan University Center for Evidence-based Nursing on 10 July 2025, with the registration number ES20258489.

PMID 43053241
阅读全文 →
PubMedClinical oral investigations2026-11-19

Intra-sulcular compound chamomile and lidocaine hydrochloride gel for procedural pain during ultrasonic scaling: a randomized, single-blind, split-mouth, sham-controlled superiority trial in adults with plaque-induced gingivitis.

Tang Rong R, Yin Tingting T, Liang Jia J, Wang Ruijie R et al.

This study aimed to evaluate whether intra-sulcular application of a compound chamomile and lidocaine hydrochloride gel (Kami-Gel) reduces procedural pain during ultrasonic supragingival scaling in adults with plaque-induced gingivitis compared with a sham procedure. A single-center, randomized, single-blind, split-mouth, sham-controlled superiority trial was conducted involving 114 adults with plaque-induced gingivitis. Participants received a sequential split-mouth treatment. The test side received intra-sulcular application of Kami-Gel, while the control side received a sham application (mimicked injection). The primary outcome was procedural pain intensity measured on a 0-10 Visual Analog Scale (VAS). Secondary outcomes included the number of pain complaints, procedural duration, patient satisfaction, and plaque index (PI). Safety was assessed immediately and at 24 h. All 114 participants completed the study. Median VAS score was significantly lower in the test group (1.7 [IQR: 0.62-2.58]) than the control group (4.1 [IQR: 2.42-5.7]), with an estimated treatment difference of - 2.35 (95% CI: -3.0 to - 1.7)-the upper limit of which fell below the pre-specified superiority margin of - 1.2, confirming superiority (P < 0.001). The test group also demonstrated significantly fewer pain complaints (median 0 vs. 1), shorter procedural duration (median 10 vs. 12 min), and higher patient satisfaction (all P < 0.001). Post-scaling plaque index was significantly lower in the test group (median 0.75 [IQR: 0.55-0.86] vs. 0.89 [IQR: 0.75-0.96]; P < 0.001), though this difference may reflect improved patient cooperation rather than a direct pharmacological effect. No adverse events were reported. Intra-sulcular application of compound chamomile and lidocaine hydrochloride gel reduces procedural pain during ultrasonic supragingival scaling compared to a sham procedure. Its use was associated with shorter active scaling time and higher satisfaction. Whether these acute benefits translate to improved long-term periodontal treatment compliance warrants further investigation. Intra-sulcular application of compound chamomile and lidocaine gel (Kami-Gel) prior to ultrasonic supragingival scaling reduces procedural pain and was associated with higher patient satisfaction. A lower post-scaling plaque index was observed in the test group, potentially attributable to improved patient cooperation during instrumentation. This safe, non-injectable chairside technique provides clinicians a practical tool to enhance patient comfort during scaling procedures.

PMID 43052462
阅读全文 →
PubMedJournal of eating disorders2026-11-19

Evidence summary for nutritional rehabilitation in patients with anorexia nervosa.

Jin Xiaochao X, Liu Yue Y, Cai Jiajia J, Luo Chen C et al.

This study aimed to systematically identify, evaluate, and synthesise evidence on nutritional rehabilitation in patients with anorexia nervosa, both domestically and internationally, to provide references for clinical practice. Relevant evidence was retrieved from domestic and international guideline websites, professional association websites, and databases, guided by the 6 S pyramid model. The search covered publications up to October 31, 2025. Four researchers independently assessed methodological quality and extracted and summarised evidence by theme. Nineteen studies were included: two clinical decision-making documents, one evidence summary, 15 guidelines, and one expert consensus. From these, 36 best-evidence items were synthesised across nine domains: multidisciplinary nutritional rehabilitation teams, nutritional rehabilitation goals, nutritional assessment, refeeding plans, approaches and principles of nutritional rehabilitation, behavioural management, complication management, psychotherapy, and nutritional education. This study systematically reviews the best available evidence for nutritional rehabilitation in patients with anorexia nervosa. In the subsequent process of evidence translation, relevant stakeholders should select evidence in a targeted manner by considering patient preferences and clinical contexts in their respective countries or regions, so as to ensure the scientificity and effectiveness of patients' nutritional rehabilitation and ultimately improve patient outcomes. Clinical trial registration Registered with the Center for Evidence-Based Nursing, Fudan University (registration number ES20258339). This study is a synthesis of best evidence and does not involve clinical trials; therefore, no clinical trial number applies.

PMID 43053123
阅读全文 →
PubMedJournal of translational medicine2026-11-19

In vitro biological evaluation of a water-soluble hyperbranched β-cyclodextrin nanocarrier for co-delivery of doxorubicin and curcumin.

Samadzadeh Meisam M, Salmanifard Ardestani Mohammad Taha MT, Zarepour Atefeh A, Khosravi Arezoo A et al.

Conventional chemotherapy is often limited by poor aqueous solubility, systemic toxicity, and low bioavailability. To address these limitations, a water-dispersible hyperbranched β-cyclodextrin (HBCD) crosslinked with 1,2,3,4-butanetetracarboxylic acid (BTCA) was developed as a nanocarrier for the co-delivery of doxorubicin (DOX) and curcumin (CUR). HBCD was synthesized under optimized conditions and characterized using complementary physicochemical techniques. DOX and CUR were loaded individually and in combination, and drug release kinetics were evaluated. Biological performance was assessed by hemolysis, cytocompatibility, cellular uptake assessment, apoptosis analyses, anticancer activity, and concentration-dependent drug interaction analysis using SynergyFinder+. The optimized HBCD exhibited favorable physicochemical properties and excellent water solubility. Encapsulation efficiencies in the co-loaded formulation reached 50.8% for DOX and 45.7% for CUR. Drug release showed an initial burst followed by sustained release over 96 h, with kinetics best described by the Korsmeyer-Peppas model. HBCD demonstrated excellent hemocompatibility (<2% hemolysis) and high cytocompatibility toward HDF cells. Drug-loaded formulations produced concentration-dependent cytotoxicity in cancer cell lines. Cellular association and apoptosis analyses confirmed the biological activity of the formulations, while SynergyFinder+ indicated predominantly additive drug interactions with localized concentration-dependent positive interaction regions rather than uniform synergism. BTCA-crosslinked water-dispersible HBCD provides an effective platform for the co-delivery of hydrophilic and hydrophobic anticancer agents, combining efficient drug loading, sustained release, hemocompatibility, and encouraging in vitro biological performance. These findings establish a foundation for future mechanistic, pharmacokinetic, and in vivo studies to further evaluate the translational potential of this delivery system.

PMID 43053162
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多doxorubicin hydrochloride